載入中
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
前收盤價
US$1.57
−US$0.17 · -9.77%
盤前
US$1.57
US$0.00 · 0.00%
10月13日 上午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
日內區間
目前US$1.57
52週區間
目前US$1.57
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
41
合理估值
情緒
58
多空交錯
風險
66
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
日內區間
目前US$1.57
52週區間
目前US$1.57
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 681.9萬 USD | 376.8萬 USD | 323.2萬 USD | 24.2萬 USD | 24.9萬 USD |
| 銷售、一般及管理費用 | 515.8萬 USD | 446.7萬 USD | 815.5萬 USD | 199.7萬 USD | 81.3萬 USD |
| 營業費用 | 1197.7萬 USD | 823.5萬 USD | 1138.7萬 USD | 223.9萬 USD | 106.2萬 USD |
| 利息收入 | 2.1萬 USD | 2.5萬 USD | — | — | — |
| 利息支出 | — | — | 208.2萬 USD | 65.3萬 USD | 54.7萬 USD |
| 折舊和攤銷 | 4000 USD | 4000 USD | 4000 USD | 3000 USD | 7.3萬 USD |
| 營業利益 | −1197.7萬 USD | −823.5萬 USD | −1138.7萬 USD | −223.9萬 USD | −106.2萬 USD |
| 淨利 | −1195.6萬 USD | −820.7萬 USD | −1303.7萬 USD | −321.7萬 USD | −155.9萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2008年12月29日 | US$0.489Irregular | — | — |
除息 2008年12月29日
US$0.489
Irregular
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
